Influenza vaccination is associated with reduced severity of community-acquired pneumonia

Pneumonia is an important cause of influenza-associated morbidity and mortality. Influenza vaccination has been shown to reduce morbidity and mortality during influenza seasons. Protection from severe pneumonia may contribute to the beneficial effect of influenza vaccination. Therefore, we investigated the impact of prior influenza vaccination on disease severity and mortality in patients with community-acquired pneumonia (CAP). Analysis from an observational, multicentre cohort study initiated by the German competence network for CAP was performed. Patients were analysed separately as an influenza season and off-season cohort. Associations between vaccination status and outcome parameters were evaluated by multivariate analyses. In the season cohort (2,368 patients) CAP in vaccinated patients was significantly less severe according to most analysed parameters (CURB index ≥1: OR 0.76, 95% CI 0.60–0.98; procalcitonin ≥2.0 ng·mL−1: OR 0.53, 95% CI 0.35–0.81; procalcitonin ≥0.5 ng·mL−1: OR 0.71, 95% CI 0.51–0.99) and these patients showed a significantly better overall survival within the 6-month follow-up period (HR 0.63, 95% CI 0.45–0.89). Within the off-season cohort (2,632 patients) there was no significant influence of vaccination status on CAP severity or disease outcome. In conclusion, prior influenza vaccination was associated with less severe clinical course and improved overall long-term survival in patients with CAP during influenza seasons.

[1]  J. Scadding.  PULMONARY complications of influenza. , 1952, Lancet.

[2]  D. E. Rogers,et al.  Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. , 1959, The Journal of clinical investigation.

[3]  E. D. Kilbourne.  Studies on influenza in the pandemic of 1957-1958. III. Isolation of influenza A (Asian strain) viruses from influenza patients with pulmonary complications; details of virus isolation and characterization of isolates, with quantitative comparison of isolation methods. , 1959, The Journal of clinical investigation.

[4]  M. Hornbrook,et al.  Influenza Vaccination Programs for Elderly Persons: Cost-Effectiveness in a Health Maintenance Organization , 1994, Annals of Internal Medicine.

[5]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Rehg,et al.  Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. , 2002, The Journal of infectious diseases.

[7]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[8]  T. van der Poll,et al.  IL-10 Is an Important Mediator of the Enhanced Susceptibility to Pneumococcal Pneumonia after Influenza Infection , 2004, The Journal of Immunology.

[9]  F. Rodríguez de Castro,et al.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome , 2004, Thorax.

[10]  T. Welte,et al.  CAPNETZ—Community-Acquired Pneumonia Competence Network , 2004, Infection.

[11]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[12]  H. Sitter,et al.  [S3-guideline on ambulant acquired pneumonia and deep airway infections]. , 2005, Pneumologie.

[13]  J. Navarro,et al.  Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. , 2005, Chest.

[14]  J. McCullers.  Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.

[15]  J. Brundage.  Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness , 2006, The Lancet Infectious Diseases.

[16]  B. Stricker,et al.  Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. , 2006, Archives of internal medicine.

[17]  K. Nichol,et al.  Effectiveness of influenza vaccine in the community-dwelling elderly. , 2007, The New England journal of medicine.

[18]  D. Fisman,et al.  Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. , 2007, Archives of internal medicine.

[19]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Cecile Viboud,et al.  Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. , 2007, The Lancet. Infectious diseases.

[21]  Pesus Chou,et al.  Impact of influenza vaccination on major cause-specific mortality. , 2007, Vaccine.

[22]  B. Lambrecht,et al.  Sustained desensitization to bacterial Toll-like receptor ligands after resolutionof respiratory influenza infection , 2008, The Journal of experimental medicine.

[23]  T. Welte,et al.  Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes , 2008, European Respiratory Journal.

[24]  Y. Hirakata,et al.  Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. , 2008, Diagnostic microbiology and infectious disease.

[25]  D. Metzger,et al.  Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection , 2008, Nature Medicine.

[26]  T. Marrie,et al.  Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? , 2008, American journal of respiratory and critical care medicine.

[27]  Matthias Mack,et al.  Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand , 2008, The Journal of experimental medicine.

[28]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[29]  W. Lim,et al.  BTS guidelines for the management of community acquired pneumonia in adults: update 2009 , 2009, Thorax.

[30]  A. Shahangian,et al.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. , 2009, The Journal of clinical investigation.

[31]  F. Sung,et al.  EFFECTIVENESS OF INFLUENZA VACCINE IN THE COMMUNITY-DWELLING ELDERLY , 2011 .